Promotions

News
BioChain Will Exhibit in AACR 100th Annual Meeting in Denver
Hayward, California (March 27, 2009)
BioChain Institute, Inc. will join AACR 100th annual meeting as an exhibitor from April 18th to April 22nd 2009.  The booth number is 853.  BioChain's representatives will offer our booth visitors various incentive plans to get Biochain's products. 

BioChain Launches BestBio^TM ELISA Kits
Hayward, California (March 26, 2009)
BioChain has brought ELISA kits to the research market for many years, more and more customers are in favor of Biochain's ELISA kits due to its high quality and low cost. All Biochain's ELISA kits are manufactured in GMP and ISO 9000 and ISO 13485 certified facilities. Biochain's BESTBio^TM ELISA kits are ideal for testing large number of clinical samples by customers from Clinical Research Organization (CRO).

BioChain Signs Distributor Agreement with Bionova in Spain
Hayward, California (March 1, 2009)
BioChain Institute, Inc. signed distributor agreement with Bionova, whose location in Spain, today.  Biochain has been getting inquiries from customers in Spain for many years, and finally find Bionova as our local distributor in Spain.  Both parties are expecting a successful collaboration. 

BioChain Gains New Patent for its Dr. P Extraction Kit
Hayward, California (February 10, 2009)
BioChain Institute, Inc. was granted a U.S. patent (Patent Number 7488579) for its Dr. P Kit on Feb. 10, 2009. The Dr. P Kit takes its name from the first letters of DNA, RNA, and Protein, and is a valuable research tool that enables researchers to isolate DNA, RNA, and Protein simultaneously from a single biomaterial source. Comparing with patent expired Trizol solution, Dr. P Kit can be used to isolate better quality and higher yield genomic DNA and protein lysate. 

BioChain Launches Human Lung Tumor Frozen Tissue Array
Hayward, California (Jan 28th, 2009)
BioChain Institute, Inc. launches lung tumor frozen tissue array, besides breast tumor frozen tissue array, prostate tumor frozen tissue array, and multiple tumor frozen tissue array, this is the 4th tumor related frozen tissue array provided by BioChain.  BioChain is currently the leader of frozen tissue array on the market.

BioChain Grants iPods to the winner in ASCB meeting
Hayward, California (Jan 7th, 2009)
BioChain Institute, Inc. send iPods to two winners during ASCB meeting.  They are Miss. Jennifer Paredes from Celgene Corporation in NJ., and Dr. Dennis Huang from Dako North America in California.

BioChain Exhibits on ASCB Annual Meeting in San Francisco Moscone Center
Hayward, California (December 10th, 2008)
BioChain Institute, Inc. will exhibit on ASCB annual meeting from December 13th to 17th, visit our booth (#2112) to get a chance to win an iPod.

BioChain launches five new products related to DNA Methylation Study, and DNA /RNA Extraction and Isolation
Hayward, California (November 3, 2008)
BioChain Institute, Inc. today introduced five new kits to the research community. Among the new products are a DNA Methylation Detection Kit, an FFPE Tissue DNA Extraction Kit, an FFPE Tissue RNA Extraction Kit, a Blood DNA Isolation Kit, and a Serum DNA Isolation Kit. As part of a Holiday Sales Promotion, Biochain is also offering all five of these new products at a special introductory price of 25% off the normal list price for a limited time.

BioChain Receives ISO9001 Certification
Hayward, California (October 16, 2008)
On October 16, 2008, BioChain Institute, Inc. officially became an ISO9001 certified company. The ISO9001 Certificate is issued by UL (Underwriters Laboratories, Inc.) with file number A17246. Gaining ISO9001 certification is an important step for BioChain because it certifies that our company maintains a high standard of quality and applies formalized business processes and procedures in our operations. View our ISO9001 Certificate.

BioChain Gains Recommendation to Become an ISO9001 Certified Company
Hayward, California (October 14, 2008)
BioChain Institute, Inc. is proud to announce that on October 14, 2008 the company was recommended by the UL DQS Registrar to become an ISO9001 certified company. The official certificate is expected to be issued within one month. UL DQS was recently formed as a result of the merger of two leading global management system registrars UL (Underwriters Laboratories), a world leader in the registration industry and DQS, the leading European registrar. The combined company serves global customers with 61 offices in 44 countries.

BioChain Launches Rodent Custom Services  
Hayward, California (October 1, 2008)
BioChain has completed the establishment of its rodent facility in the San Francisco Bay area. The facility is currently hosting major strains of inbred and outbred mice, rats, and hamsters. This facility is fully AAALAC accredited. With this state-of-the-art facility and experienced group of scientists and technicians, BioChain is well-positioned as a premium service provider in contract animal research. BioChain Institute is dedicated to providing our clients a wide range of preclinical contract animal research services designed to support various biological and pharmaceutical studies. These services range from pharmacokinetics, toxicology studies to the complete outsourcing of entire animal studies.

BioChain Introduces Calcium Channel Cell Lines  
Hayward, California (September 29, 2008)
BioChain Institute, Inc. today launched a new product within the cells and culture medium product category called Calcium Channel Cell Lines. This product promises to be a valuable tool in in the research of various neurological and cardiovascular disorders as well as in potential pharmacological treatments for pain and epilepsy.         

BioChain Introduces Mouse Feeder Cells       
Hayward, California (September 25, 2008)
BioChain Institute, Inc. today launched a new product, Mouse Embryonic Fibroblast (MEF) cells as feeder layers for stem cell culture to the research community. BioChain now offers a wide selection of MEF cells including neomycin resistant, DR4 (resistant to neomycin, hygromycin, puromycin and 6-thioguanine) and CF-1 MEF cells. We offer both untreated or gamma irradiated MEF cells. Every single batch of MEF cells is tested for its ability to support undifferentiated mESC growth and is mycoplasma negative. Early passages (P2) are provided for further expansion if more cells are needed.

BioChain Introduces Primate Animal Model Services     
Hayward, California (September 22, 2008)
BioChain Institute, Inc. today introduced its Primate Animal Model Service to the research community. According to FDA regulations, all drug candidates for Neurological diseases, such as Alzheimer's disease and Parkinson's disease, must pass nonhuman primate animal tests before processing into clinical trials.  In addition, all cell-based therapies and gene-therapies are also required to go through nonhuman primate animal tests before advancing to a phase I clinical trial.  Nonhuman primate animal models need to be established for the research of the following important human diseases, such as AIDS, SARS, autoimmune system diseases, old age diseases, and other gene defective diseases. Biochain has teamed up with contract research organizations (CROs), which are fully accredited by AAALAC international, and exclusively focus on primate resources.  We have a very strong team of scientists, researchers, veterinarians, and technicians, who are actively engaged in developing nonhuman primate models for studies of drug safety, drug pharmacokinetics, drug efficacy, and cell and gene therapies, particularly for neurological disorders and aging-related diseases.

BioChain Beijing Division completes GLP lab for clinical sample preparation    
Hayward, California (August 22, 2008)
The completion of the GLP lab will enable BioChain to provide an expanded array of research functions. The new GLP lab is equipped to handle molecular diagnostics research including both clinical sample preparation and testing. GLP management controls are extremely valuable because they help assure regulatory authorities that the data submitted are a true reflection of the results obtained during a study and can therefore be relied upon when making safety assessments.   See Image

BioChain attends the 2008 BIO International Convention in San Diego, CA     
Hayward, California (June 17-20, 2008)
BioChain attended this year’s BIO International Convention as an exhibitor and presented key product lines including FDA standard frozen tissue arrays, endothelial progenitor cell (EPC) products (consisting of primary cells and reagents, recombinant cell lines, and cell-based assays), and our xenograft service. More than 20,000 people attended this year’s convention, and many attendees showed great interest in BioChain’s products while visiting our exhibition booth. BioChain received positive feedback from new and potential customers and made many useful business contacts at the convention. If you were unable to attend the 2008 BIO International Convention, please contact us for more information about the products our company presented. See Image

BioChain Launches Xenograft Services
Hayward, California (March 1, 2008)
BioChain Institute Inc. today introduced Living Tumor xenograft models, which are developed using human tumor tissues grafted in subrenal capsules of SCID mice. The human tumor tissues are developed into transplantable tumor tissue lines. These tumor tissue lines offer sustainable tumor sources for xenograft models. The model is in many aspects superior to conventional tumor model systems which are based on cultured cancer cell lines.

BioChain Launches Endothelial Progenitor Cells (EPCs)
Hayward, California (February 1, 2008)
BioChain Institute Inc. today introduced Endothelial Progenitor Cells (EPCs). EPCs play an important role in both angiogenesis and vasculogenesis. Compared to specific mature types of endothelial cells such as HMVEC and HUVEC, EPC are more suitable for cell-based screening of anti-cancer drugs. In addition, EPC have impact on aging and smoking-related diseases, suggesting potential uses of EPC in these areas.

BioChain Launches Breast Tumor Frozen Tissue Array
Hayward, California (February 1, 2008)
BioChain Institute Inc. today introduced Breast Tumor Frozen Tissue Array.  This array is designed for studying breast tumor tissue specific cellular localization of genes or proteins of interest in breast tissues. Breast tumors from 37 different donors and 3 corresponding normal tissues are mounted on positively charged glass slides.

BioChain Launches Lateral Flow Assay Kit for Tuberculosis (TB)
Hayward, California (January 8, 2008)
BioChain Institute Inc. today introduced lateral flow assay kit - Rapid Gold Immuno-assay Kit for Antibody IgG to Tuberculosis to test TB.  The test is very easy to operate and only takes 15-20 minutes.

BioChain Launches more ELISA Kits
Hayward, California (January 8, 2008)
BioChain Institute Inc. today introduced TORCH ELISA kits, which are designed for testing Toxoplasmosis, CMV, Rubella, HSV.  TORCH test measures the levels of an infant's antibodies against these five groups of chronic infections.  Biochain also introduced Anti-HEV IgG and Anti-HEV IGM ELISA kits at the same time.

BioChain Launches EasyXpress Viral Nucleic Acid Release Kit
Hayward, California (January 8, 2007)
BioChain Institute Inc. today introduced the EasyXpress Viral Nucleic Acid Release Kit, which is designed for the rapid isolation of small quantities of viral RNA or DNA from cell culture supernatants and biological samples in microfuge tubes or in a 96-well format for subsequent quantitative and real-time RT-PCR analysis. The kit contains VNAR Protease, a proprietary mixture of buffers and proteases that allow for the isolation of up to 96 viral nucleic acid samples in under an hour with no sample filtration or precipitation steps.

BioChain Launches TeloExpress Quantitative Telomerase Detection Kit
Hayward, California (January 8, 2008)
BioChain Institute Inc. today introduced TeloExpress Quantitative Telomerase Detection Kit.  The ends of linear human chromosomes terminate with telomers that consist of a tandem repeat of the sequence TTAGGG.  The telomerase enzyme is a ribonucleoprotein that synthesizes these telomeric DNA repeat sequences. Telomerase activity is low in healthy cells and increased in a variety of malignancies and in immortalized cells.

BioChain Launches High Throughput RNA/DNA isolation kits from Tissues/Cells/Blood in 96 Well Plate Format
Hayward, California (January 1, 2008)
BioChain Institute Inc. today introduced EZ-RNA 96 Kit, EZ-DNA 96 Kit, EZ-Blood RNA 96 Kit, and EZ-Blood DNA 96 Kit.  These kits are designed for the high-throughput purification of total cellular RNA genomic DNA from cultured cells, tissues, and blood in a 96-well plate format. No phenol-chloroform extraction or precipitation steps are involved.

BioChain Launches Neurological Diseased Frozen Tissue Section Panel
Hayward, California (September 9, 2007)
BioChain Institute Inc. today introduced neurological diseased frozen tissue section panels.  The first panel series are Alzheimer's diseased panels.  These panels are validated by IHC with beta amyloid plaque.

BioChain Enlarges Product Lines from Neurological Diseased Tissues
Hayward, California (April 30, 2007)
Besides Alzheimer's diseased products, we have added PCR Ready First Strand cDNA, genomic DNA, total protein lysate, frozen tissue sections, and paraffin tissue sections from different regions of Parkinson's Disease, Dementia, Multiple Sclerosis, Progressive Supranuclear Palsy (PAP), and Depression diseased brain tissues. More organs maybe available upon request.

BioChain Enlarges Product Lines from Diabetes Diseased Tissues
Hayward, California (April 23, 2007)
PCR Ready First Strand cDNA, genomic DNA, total protein lysate, frozen tissue sections, and paraffin tissue sections from different organs of Diabetes diseased donors are available. More organs maybe available upon request.

BioChain Launches Products from Lung Diseased Tissues
Hayward, California (April 16, 2007)
PCR Ready First Strand cDNA, genomic DNA, total protein lysate, frozen tissue sections, and paraffin tissue sections from human asthma, bronchitis, pneumonia, and pulmonary embolism lung diseased tissues are available. More organs maybe available upon request.

BioChain Enlarges Products from Heart Diseased Tissues
Hayward, California (April 9, 2007)
PCR Ready First Strand cDNA, genomic DNA, total protein lysate, frozen tissue sections, and paraffin tissue sections from hypertension, coronary artery disease, arteriosclerosis, congestive heart failure heart diseased tissues are available. More organs maybe available upon request.

BioChain Enlarges Universal Reference Product Lines by Adding more Species
Hayward, California (March 11, 2007)
BioChain Institute Inc. has completed its Universal Reference Products: Universal RNA, Universal cDNA, and Universal Protein Lysate by adding 3 more species: monkey, dog, and chicken. These products are ideal controls for high throughput PCR, cDNA microarray, antibody array studies.

BioChain Launches a new FDA standard Frozen Tissue Array
Hayward, California (February 9, 2007)
BioChain Institute Inc. today introduced the industry's first FDA standard Frozen Tissue Array which is suitable for antibody validation for cross reactivity analyses under US FDA requirements. The array can also be applied into IVD (In vitro Diagnostic Devices) certification and also European CE Mark. There are two slides in a set of FDA standard frozen tissue array which contains 30 different human normal frozen tissues sections and 3 donors per tissue type. It helps to analyze antibody cross reactivity once for all tissues in three donors required by FDA regulation. It will save tremendous labor and time. More importantly it helps to speed up FDA approval process.

One Step Coupling Method with GoldMag Magnetic Beads and Immobilization Starter Kit
Hayward, California (November 8, 2006)
The GoldMag Bead is a novel paramagnetic particle, in which the magnetic core is coated with a layer of gold. A key benefit of this technology is its ability to capture and concentrate more antigens from a variety of complex biological matrices compared to conventional ELISA. Antibody-captured materials are then separated rapidly from the surroundings when placed in a magnetic field. The GoldMag beads appear various colors as function of its bead size so that can be potentially applied into multiplexing bio-molecular separation and detection.

MicroRNA Isolation and Detection with BioChain Institute's Micro RNA System
Hayward, California (September 1, 2006)
Biochain MicroRNA isolation and detection kits are now available to life scientist who will like to have a faster and less cost method to purify and quantify microRNA or the other small RNA from tissue and the other sources. The benefits of Biochain's isolation and detection system are 1) It can be used to isolate either small RNA (<200nt) or large RNA (>200nt) within 30 minutes; 2) It is a one-step only and simple method to detect MicroRNA with higher sensitivity and lower background than key competitor's kit currently on the market.

Biochain has New Distributors in Czech Republic and India (April 2005)
Biochain announces today that it has granted distribution authority to Biogen Praha s.r.o. of Czech Republic and  KRISHGEN BioSystems of India. 

Biochain has New Distributors in Japan and India (April 2005)
Biochain announces today that it has granted distribution authority to Cosmo Bio Co., Ltd. of Japan and  Life Technologies (India) Pvt. Ltd. of India. 

Biochain to provide frozen tissue array (September 20, 2004)
Biochain launched today the new frozen tissue array. Its frozen Tissue Array is made from the same high quality tissues used in our frozen tissue slide products. Fresh frozen tissues are arrayed on positively charged glass slides. 

Biochain to provide frozen tissue section panel (July 19, 2004)
BioChain launched today the new frozen tissue section panels. The panels are made from the same high quality tissues used in the frozen tissue slide products. The frozen tissue section panels are one of the best products for rapid detection of gene and protein expression in a wide variety of tissues.

Biochain Announces Launch of New Products of New Species (April 2004)
BioChain announced today the launch of new cDNA, Genomic DNA, RNA, and Protein products of cynomolgus monkeys. By now, BioChain supplies product lines from both cynomolgus and rhesus monkeys.  

BioChain Attended Molecular Medicine Tri-Conference (March 23-26, 2004)
BioChain attended as an exhibitor Molecular Medicine Tri-Conference held in San Francisco, California on March 23-26, 2004. Molecular Medicine Tri-Conference converged key thought-leaders across the drug discovery and development spectrum.

Biochain Announces Investment in Yuantai Ltd, a Monoclonal Antibody Company in China (February 2004)
BioChain Announced today it has invested in Yuantai, Ltd., a monoclonal antibody company in China. Yuantai has a capability of producing more than 300 monoclonal antibodies and 200 recombinant proteins annually. Yuantai has granted BioChain exclusive rights for distributing its products worldwide.